Showing results (61-70 of 94) with videos related to

Sort By:
Pageof 10
Postgraduate Medicine|April 28, 2015
Low-dose SoluMatrix diclofenac in the treatment of osteoarthritis: A 1-year, open-label, Phase III safety studyRoy D Altman, Vibeke Strand, Marc C Hochberg, et al.
Rheumatology (Oxford, England)|October 25, 2022
Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 2 studyAndrew Östör, Filip Van den Bosch, Kim Papp, et al.
Annals of the Rheumatic Diseases|April 8, 2020
Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging studyDésirée van der Heijde, Lianne S Gensler, Atul Deodhar, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 10, 2025
Efficacy and Safety of ABBV-154 for the Treatment of Active Rheumatoid Arthritis: A Phase 2b, Randomized, Placebo-Controlled TrialFrank Buttgereit, Atul Singhal, Alan Kivitz, et al.
The Journal of Rheumatology|December 17, 2017
Two-year Efficacy and Safety of Subcutaneous Tocilizumab in Combination with Disease-modifying Antirheumatic Drugs Including Escalation to Weekly Dosing in Rheumatoid ArthritisAlan Kivitz, Ewa Olech, Michael A Borofsky, et al.
Rheumatology and Therapy|April 17, 2023
Phase 2 Dose-Finding Study in Patients with Gout Using SEL-212, a Novel PEGylated Uricase (SEL-037) Combined with Tolerogenic Nanoparticles (SEL-110)Alan Kivitz, Wesley DeHaan, Rehan Azeem, et al.
Pain and Therapy|November 18, 2021
Improved Treatment Effect of Triamcinolone Acetonide Extended-Release in Patients with Concordant Baseline Pain Scores on the Average Daily Pain and Western Ontario and McMaster Universities Osteoarthritis Index Pain ScalesEdgar Ross, Nathaniel P Katz, Philip G Conaghan, et al.
Annals of the Rheumatic Diseases|November 24, 2021
Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trialAndrew Östör, Filip Van den Bosch, Kim Papp, et al.
Annals of the Rheumatic Diseases|November 6, 2021
Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 yearsKevin L Winthrop, Yoshiya Tanaka, Tsutomu Takeuchi, et al.
Arthritis and Rheumatism|June 28, 2006
Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trialDésirée van der Heijde, Alan Kivitz, Michael H Schiff, et al.
Pageof 10